Overcome ADC Challenges from Design to IND-Enabling Studies
Antibody Drug Conjugates (ADCs) are among the fastest growing drug classes in oncology, with more than 13 ADCs approved for various cancer indications. The field of ADCs continues to evolve rapidly with ongoing efforts aimed at addressing tumor heterogeneity, drug resistance, and optimization of the therapeutic window. Recent strides in ADC research have prioritized enhancing efficacy, safety, and tumor specificity.
This webinar presents a full framework for ADC design, synthesis, characterization, and in vivo efficacy aimed at expediting the transition of novel ADCs from discovery to clinical applicability. Using an immuno-oncology case study, it describes a robust workflow with a particular emphasis on potency, efficacy, and safety profiling.
Topics covered include the generation and purification of various antibody formats, the synthesis and optimization of ADCs, and comprehensive off-target screening efforts. The webinar also reviews in vitro assays used to assess the risk, potency, and selectivity of lead ADC candidates, as well as efficacy testing in translational relevant in vivo models.
Key Learning Objectives:
- Learn how phage display libraries enable the discovery of clinic-ready antibody binders
- Discover how our proprietary Retrogenix screening platform facilitates safety assessments
- Understand the in vitro pharmacology and safety assays driving ADC discovery forward
- Learn how to select the most suitable in vivo models related to drug development objectives and how PDX efficacy models are facilitating translational pharmacology studies
Webinar Presenters
Kathrin Zuberbühler, PhD
Associate Director Antibody Engineering
Charles River
Namrata Jayanth, PhD
Biotherapeutics Research Leader
Charles River
Julia Schueler, DVM, PhD
Therapeutic Area Lead Oncology
Charles River